

RECEIVED
CENTRAL FAX CENTER

FEB 03 2005

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Appln. Ser. No.:	Filed:	Inventor(s):	Atty Dkt:
09/891,881	06/26/2001	J. Voorhees	100UM-010A
Title: Use of EGF-R Protein Tyrosine Kinase Inhibitors			
Examiner: R. Winston		Art Unit: 1654	

BEST AVAILABLE COPY

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


VIA FACSIMILE
571-273-8300

RESPONSE and AMENDMENT

Dear Sir:


In complete response to the Office action mailed 8 June 2004, and the Notice of Non-Compliant Amendment mailed 25 January 2005, please first amend the claims as shown on the following four pages, after which are remarks.

Respectfully submitted,


Bradley N. Ruben, Reg. No. 32,058
Bradley N. Ruben, PC
463 First St., Suite 5A
Hoboken, NJ 07030-1859
201-239-0707 (fax -0734)
mail@rubenpatent.com
3 February 2005

CERTIFICATE OF MAILING OR
TRANSMISSION - 37 CFR 1.8

I hereby certify that I have a reasonable basis that this paper, along with any referred to above, (i) are being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, or (ii) are being transmitted to the U.S. Patent & Trademark Office in accordance with 37 CFR § 1.6(d).

DATE: 3 Febury 2005
NAME: Brad Ruben
SIGNATURE: 

09/891,881

Page 1 of 9

100UM-010A